Loading companies…
WG
WhiteLab Genomics
United States · Biotech
WhiteLab Genomics uses AI to design genetic medicines and develop bio-assets for cell, RNA and DNA therapies.
Product
WhiteLab Genomics has built an AI platform to accelerate the discovery and design of genomic therapies, including cell, RNA and DNA treatments. The company develops computationally designed bio-assets and is advancing programs toward in vivo validation. Its work connects AI-driven design with experimental validation to help create the next generation of genomic medicines.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $26M | AVP — LeadBlast Club — ParticipantDebiopharm Innovation Fund — ParticipantOmnes Capital — ParticipantYaday Health — Participant |
Investors
AVPLed Series BBlast ClubJoined Series BDebiopharm Innovation FundJoined Series BOmnes CapitalJoined Series BYaday HealthJoined Series BCoverage
Oct 6, 2026WhiteLab Genomics · Series BSimilar companies
ASAutopoiesis SciencesAutopoiesis Sciences is developing AI research tools that help scientists plan and carry out scientific discovery.$11M · Seed
SBSensible BiotechnologiesA platform for designing and manufacturing naturally modified mRNA medicines.$47M · Series A
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B